Literature DB >> 36038674

Repeat hepatectomy for pediatric recurrent chemotherapy-resistant hepatoblastoma: a report of 18 cases.

Xiaoran Li1,2, Zheng Wang3, Dongpo Zhang3, Di Zhao2, Jindong Ye2, Weihong Duan2, Liuxin Duan4, Quanda Liu5,6,7.   

Abstract

BACKGROUND AND AIMS: Repeat hepatectomy for adult recurrent hepatocellular carcinoma significantly prolongs the overall survival, but repeat hepatectomy for pediatric recurrent hepatoblastoma (HB) is rarely reported, and the outcomes are warranted to be investigated.
METHODS: All patients between May 2015 and December 2020 with recurrent HB after intended surgical cure were retrospectively evaluated. Clinicopathologic features, surgical details and outcomes were analyzed during a median following-up of 24 months after repeat hepatectomy. Survival analysis was performed using the Kaplan-Meier estimate.
RESULTS: A total of 18 patients of recurrent HB undergoing repeat hepatectomy with radical cure intention were included. There were 11 males and 7 females. The median age was 29 months (range 5-87 months) at first hepatectomy, and the median time to the recurrence from the first hepatectomy was 7 months. The operating time of the repeat hepatectomy was 5.0 h (range 3.5-9.0 h) and the mean blood loss was 592 ml (range 50-3200 ml). Radical resection (R0) was achieved in 12 patients (66.7%), with a postoperative hospital stay of 7.9 ± 1.8 days. No serious postoperative complications or mortality occurred. The overall survival (OS) rate was 55.6% (10/18) and the event-free survival (EFS) rate was 33.3% (6/18). Those with no lung metastases, not high-risk stratification, and achieving R0 hepatectomy, anatomic hepatectomy had longer OS rate (all P < 0.05) after repeat hepatectomy. Two of three patients with re-recurrence HB undergoing salvage liver transplantation were alive with a tumor-free survival.
CONCLUSIONS: Repeat hepatectomy for recurrent HB can be carried out safely. However, only a highly selected subgroup of patients might actually benefit from this procedure.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Children; Hepatectomy; Hepatoblastoma; Outcome; Recurrence; Repeat

Year:  2022        PMID: 36038674     DOI: 10.1007/s00432-022-04291-9

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.322


  24 in total

1.  Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT.

Authors:  Tomoro Hishiki; Tadashi Matsunaga; Fumiaki Sasaki; Michihiro Yano; Kohmei Ida; Hiroshi Horie; Satoshi Kondo; Ken-Ichiro Watanabe; Takaharu Oue; Tatsuro Tajiri; Arata Kamimatsuse; Naomi Ohnuma; Eiso Hiyama
Journal:  Pediatr Surg Int       Date:  2011-01       Impact factor: 1.827

Review 2.  Contemporary management of hepatoblastoma.

Authors:  Einar Hafberg; Scott C Borinstein; Sophoclis P Alexopoulos
Journal:  Curr Opin Organ Transplant       Date:  2019-04       Impact factor: 2.640

3.  Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial.

Authors:  Howard M Katzenstein; Max R Langham; Marcio H Malogolowkin; Mark D Krailo; Alexander J Towbin; Mary Beth McCarville; Milton J Finegold; Sarangarajan Ranganathan; Stephen Dunn; Eugene D McGahren; Gregory M Tiao; Allison F O'Neill; Muna Qayed; Wayne L Furman; Caihong Xia; Carlos Rodriguez-Galindo; Rebecka L Meyers
Journal:  Lancet Oncol       Date:  2019-04-08       Impact factor: 41.316

4.  Outcome and Late Complications of Hepatoblastomas Treated Using the Japanese Study Group for Pediatric Liver Tumor 2 Protocol.

Authors:  Eiso Hiyama; Tomoro Hishiki; Kenichiro Watanabe; Kohmei Ida; Yuka Ueda; Sho Kurihara; Michihiro Yano; Ken Hoshino; Akiko Yokoi; Yuichi Takama; Yuki Nogami; Tomoaki Taguchi; Makiko Mori; Kentaro Kihira; Osamu Miyazaki; Hiroshi Fuji; Shohei Honda; Tomoko Iehara; Takuro Kazama; Junya Fujimura; Yukichi Tanaka; Takeshi Inoue; Tatsuro Tajiri; Satoshi Kondo; Takaharu Oue; Kenichi Yoshimura
Journal:  J Clin Oncol       Date:  2020-05-18       Impact factor: 44.544

5.  Surgical management of locally-advanced and metastatic hepatoblastoma.

Authors:  Charissa M Lake; Gregory M Tiao; Alexander J Bondoc
Journal:  Semin Pediatr Surg       Date:  2019-11-13       Impact factor: 2.754

Review 6.  Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy.

Authors:  Piotr Czauderna; Dolores Lopez-Terrada; Eiso Hiyama; Beate Häberle; Marcio H Malogolowkin; Rebecka L Meyers
Journal:  Curr Opin Pediatr       Date:  2014-02       Impact factor: 2.856

7.  Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma.

Authors:  Tadashi Matsunaga; Fumiaki Sasaki; Mutsuro Ohira; Kohei Hashizume; Akira Hayashi; Yutaka Hayashi; Hideo Mugishima; Naomi Ohnuma
Journal:  Pediatr Surg Int       Date:  2003-05-24       Impact factor: 1.827

8.  Pilot study of the combination of sorafenib and fractionated irinotecan in pediatric relapse/refractory hepatic cancer (FINEX pilot study).

Authors:  Dai Keino; Tomoko Yokosuka; Ayana Hirose; Yukari Sakurai; Wataru Nakamura; Sachio Fujita; Akiko Hayashi; Naoyuki Miyagawa; Fuminori Iwasaki; Satoshi Hamanoue; Masakatsu Yanagimachi; Masae Shiomi; Shoko Goto; Norihiko Kitagawa; Mio Tanaka; Kumiko Nozawa; Yukichi Tanaka; Hiroaki Goto
Journal:  Pediatr Blood Cancer       Date:  2020-08-15       Impact factor: 3.167

9.  Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.

Authors:  Daniel Dindo; Nicolas Demartines; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

Review 10.  Models for Understanding Resistance to Chemotherapy in Liver Cancer.

Authors:  Jose J G Marin; Elisa Herraez; Elisa Lozano; Rocio I R Macias; Oscar Briz
Journal:  Cancers (Basel)       Date:  2019-10-29       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.